Chronic obstructive pulmonary disease exacerbation resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 33: Line 33:
==Management==
==Management==
{{Family tree/start}}
{{Family tree/start}}
{{Family tree |border=2|boxstyle=background:WhiteSmoke; padding:2em | | | | A01 | | | |A01=
{{Family tree |border=2|boxstyle=background: WhiteSmoke; padding: 1em | A01 | | | |A01=
<div style="text-align: left; width: 10em">'''COPD Exacerbation''' <BR> ❑ '''[[Cough]]'''↑ <BR> ❑ '''[[Dyspnea]]'''↑ <BR> ❑ '''[[Sputum]]'''↑ </div>}}
<div style="text-align: left; width: 10em">
{{Family tree | | | | |!| | | | | }}
'''COPD Exacerbation''' <BR> ❑ Cough ↑ <BR> ❑ Dyspnea ↑ <BR> ❑ Sputum ↑  
{{Family tree | | | | B01 | | | |B01=Admission}}
</div>}}
{{Family tree | | | | |!| | | | |}}
{{Family tree |!| | | | | }}
{{Family tree | | | | C01 |~| C02 | |C01='''Assessment''' :<br>1-O2 sat+ ABG <br>2-[[CXR]] <br>3-[[EKG]] <br>4-[[CBC]]
{{Family tree |border=2|boxstyle=background:WhiteSmoke; padding:1em |)|-|AA1| | |AA1=
<br>
<div style="text-align: left; width: 41em">'''Indications for Hospital Assessment or Admission'''
'''Management:''' <br>1-Inhaled bronchodilators <br>2-Systemic corticosteroids <br>3-Empirical antibiotics <br>4-O2 (target Sat >90%)| C02='''Corticosteroids(Solumedrol)'''<br>Methylprednisolone 125 mg×1 dose <br> followed with 60-80 mg Q8-12based on severity <br> IV Solumedrol to PO Prednisone taper 4--60 mg Q 8-12<br> 2-5 days taper depending on severity<br> '''Antibiotics'''<br>'''Group A'''*<br>Doxycycline Cap '''Vibramycin''' PO 100 mg Q12H<br>(if unable to tolerate choose Cefpodoxime Tab '''Vantin''' PO 200 mg Q12H)<br>'''Group B'''*<br>Ceftriaxone Inj '''Rocephin''' 1GM D5W50 ml Q24H 200 ml/Hr<br>(If Beta-Lactam allergy choose Levofloxacin Tab '''Levaquin''' PO 500 mg daily )<br> '''Group C'''*<br>Ciprofloxacin Tab '''Cipro'''PO 250 Daily <br>or Ciprofloxacin Inj Cipro 400 mg premixed at 400 mg /200 ml Q12H 200 ml/Hr.  
❑ Marked increase in intensity of symptoms (eg, sudden development of resting dyspnea) <BR> ❑ Severe underlying COPD <BR> ❑ Onset of new physical signs (eg, cyanosis, peripheral edema) <BR> ❑ Failure of an exacerbation to respond to initial medical management <BR> ❑ Presence of serious comorbidities (e.g., heart failure or newly occurring arrhythmias) <BR> ❑ Frequent exacerbations <BR> ❑ Older age <BR> ❑ Insufficient home support
}}
</div>}}
{{Family tree | | | | |!| | | | |}}
{{Family tree | | | | D01 | | | |D01=Respiratory acidosis? OR <br> PH≤35? OR<br> PaCo2≥45? OR<br> Severe signs of dyspnea? OR <br>Accessory muscles use, <br>paradoxical motion of abdomen,<br> retraction of intercostal space}}
{{Family tree | | |,|-|^|-|.| | }}
{{Family tree | E01 | | | E02 |E01=No | E02= Yes}}
{{Family tree | |!| | | | |!| |}}
{{Family tree | F01 | | | F02|F01=Continue the same management |F02='''ICU Admission''' <br>'''NIV''' }}
{{Family tree | | | | | | |!| |}}
{{Family tree | | | | | | G01 |G01= Unable to tolerate NIV?<br> Severe hemodynamic instability?<br>Resp/cardiac arrest ?  }}
{{Family tree | | | | | | |!| | |}}
{{Family tree | | | | | | H01 | |H01=Invasive mechanical ventilation}}
{{Family tree/end}}
{{Family tree/end}}
'''*Group A''':mild exacerbation, no risk factors, 2>symptoms present
'''Group B''':Mod Exacerbation w/risk factors for poor outcomes:comorbid disease, severe COPD, Frequent exacerbation>3, Antimicrobial use within the last 3 months
'''Group C''':Severe exacerbation w/risk factors for P.aeruginosa infection.


==Do's==
==Do's==

Revision as of 01:58, 11 December 2013

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Definition

  • An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication.[1][2][3]
  • The diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.[4]

Causes

Life Threatening Causes

Include conditions which may result death or permanent disability within 24 hours if left untreated, and some of them may mimic and/or aggravate exacerbations:

Common Causes

Differential Diagnosis

Management

COPD Exacerbation
❑ Cough ↑
❑ Dyspnea ↑
❑ Sputum ↑

 
 
 
 
 
 
 
 
 
 
 
 
 
Indications for Hospital Assessment or Admission

❑ Marked increase in intensity of symptoms (eg, sudden development of resting dyspnea)
❑ Severe underlying COPD
❑ Onset of new physical signs (eg, cyanosis, peripheral edema)
❑ Failure of an exacerbation to respond to initial medical management
❑ Presence of serious comorbidities (e.g., heart failure or newly occurring arrhythmias)
❑ Frequent exacerbations
❑ Older age
❑ Insufficient home support

 
 
 
 

Do's

  • Monitor fluid balance,nutrition and patient condition closely.
  • Consider subcutaneous heparin or low molecular weight heparin.
  • Treat associated conditions if exist(e.g., heart failure,arrhythmias).

Don'ts

  • Spirometry is not recommended during an exacerbation because it can be difficult to perform and measurements are not accurate enough.

References

  1. Burge, S.; Wedzicha, JA. (2003). "COPD exacerbations: definitions and classifications". Eur Respir J Suppl. 41: 46s–53s. PMID 12795331. Unknown parameter |month= ignored (help)
  2. Celli, BR.; Barnes, PJ. (2007). "Exacerbations of chronic obstructive pulmonary disease". Eur Respir J. 29 (6): 1224–38. doi:10.1183/09031936.00109906. PMID 17540785. Unknown parameter |month= ignored (help)
  3. Rodriguez-Roisin, R. (2000). "Toward a consensus definition for COPD exacerbations". Chest. 117 (5 Suppl 2): 398S–401S. PMID 10843984. Unknown parameter |month= ignored (help)
  4. Vestbo, J.; Hurd, SS.; Agustí, AG.; Jones, PW.; Vogelmeier, C.; Anzueto, A.; Barnes, PJ.; Fabbri, LM.; Martinez, FJ. (2013). "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary". Am J Respir Crit Care Med. 187 (4): 347–65. doi:10.1164/rccm.201204-0596PP. PMID 22878278. Unknown parameter |month= ignored (help)